(Q36122836)

12 August 2017

1 reference

title

Statins and cholesterol lowering after a cancer diagnosis: why not? (English)

1 reference

12 August 2017

1 reference

Mark A Moyad

1

1 reference

12 August 2017

Gregory S Merrick

series ordinal

2

1 reference

12 August 2017

publication date

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

23

1 reference

12 August 2017

issue

1

1 reference

12 August 2017

page(s)

49-55

1 reference

C-reactive protein levels and outcomes after statin therapy

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Regulation of the mevalonate pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

The potential of statins as part of anti-cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Hypocholesterolaemia and increased elimination of low-density lipoproteins in metastatic cancer of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Lovastatin potentiates the photocytotoxic effect of photofrin II delivered to HT29 human colonic adenocarcinoma cells by low density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Effect of lovastatin alone and as an adjuvant chemotherapeutic agent on hepatoma tissue culture-4 cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Interaction of cytosine arabinoside and lovastatin in human leukemia cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Inhibitory effect of statins on the proliferation of human breast cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Co-administration of simvastatin and cytotoxic drugs is advantageous in myeloma cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Cyclin E deregulation alters the biologic properties of ovarian cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Mutual amplification of apoptosis by statin-induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

The Risk of Cancer in Users of Statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Melanoma chemoprevention: a role for statins or fibrates?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humans--in vitro and in vivo studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Security and maximal tolerated doses of fluvastatin in pediatric cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Natural History of Early, Localized Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

ACTIVE SURVEILLANCE WITH SELECTIVE DELAYED INTERVENTION: USING NATURAL HISTORY TO GUIDE TREATMENT IN GOOD RISK PROSTATE CANCER

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Cancer surpasses heart disease as leading cause of death for all but the very elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Statin use and survival outcomes in elderly patients with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.03.017

10.1016/J.UROLONC.2005.03.017

7 January 2021

Identifiers

DOI

1 reference

12 August 2017

1 reference